Profil
Thomas Hazel worked as the Chief Science Officer at Innovative Biosensors, Inc. from 2004 to 2008.
He then worked at Seneca Biopharma, Inc. from 1998 to 2021, where he held the position of Senior Vice President-Research & Development from 2020 to 2021.
Hazel received his undergraduate degree from Kalamazoo College and his doctorate degree from the University of Illinois.
Anciens postes connus de Thomas Hazel
| Sociétés | Poste | Fin |
|---|---|---|
| PALISADE BIO, INC. | Directeur Technique/Scientifique/R&D | 17/03/2021 |
Innovative Biosensors, Inc.
 Innovative Biosensors, Inc. Medical SpecialtiesHealth Technology Innovative Biosensors, Inc. develops, manufactures and markets pathogen detection and diagnostic systems. Its systems comprises of biosensors that generate results at previously unseen levels of sensitivity and specificity. The firm also offers bioflash-dx, a diagnostics platform for the testing of infectious and other human diseases. The company was founded by Joe Hernandez in 2003 and is headquartered in Rockville, MD. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Formation de Thomas Hazel
| Kalamazoo College | Undergraduate Degree |
| University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Innovative Biosensors, Inc.
Innovative Biosensors, Inc. Medical SpecialtiesHealth Technology Innovative Biosensors, Inc. develops, manufactures and markets pathogen detection and diagnostic systems. Its systems comprises of biosensors that generate results at previously unseen levels of sensitivity and specificity. The firm also offers bioflash-dx, a diagnostics platform for the testing of infectious and other human diseases. The company was founded by Joe Hernandez in 2003 and is headquartered in Rockville, MD. | Health Technology |
Seneca Biopharma, Inc.
 Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
